How much does relapse after one year erode effectiveness of smoking cessation treatments? Long term follow up of randomised trial of nicotine nasal spray
John A Stapleton, Gay Sutherland, Michael A H Russell Recent research on treatments to stop smoking has focused almost entirely on nicotine replacement, and several meta-analyses testify to the efficacy of four delivery systems. 1 Although the ultimate goal of treatment is lifelong cessation, few trials have published results of abstinence beyond one year. Little consideration has therefore been given to whether the treatment is effective in reducing the major health risks of smoking. This effect would become evident only after many years of abstinence. Our randomised trial showed that the use of nicotine nasal spray compared with a placebo spray was associated with more than double the number of abstainers at one year. 2 We report the results from a longer term follow up to estimate the impact of relapse after one year on effectiveness.
Subjects, methods, and results
A total of 227 heavy smokers entered the trial; 116 were given the nicotine spray and 111 the placebo. Of these, 47 sustained abstinence from smoking for 1 year. They constituted the long term follow up group; 33 were in the nicotine group, 14 in the placebo group. Criteria for long term sustained abstinence were the same as for the first year. Since the follow up was completed mainly over a 2 month period, the time interval from randomisation varied according to when the smoker entered the trial over 15 months. Standard survival methods were used to analyse the data. Survival times of those who were not contacted beyond 1 year (3 subjects in the nicotine group, 2 in the placebo group) and those who had successfully given up were censored at their last follow up. The Kaplan-Meier method was used to estimate cumulative abstinence up to 3 Relapse after 1 year's abstinence was similar in the two groups and totalled 23% at 2 years, 38% at 3 years and 48% (95% confidence interval 32% to 64%) at 3 1 2 years. Although subjects had been recommended to use the spray for three months only, they were allowed to continue for 1 year. Of those remaining abstinent in the nicotine group, 19 used the spray for 1 year and 14 for < 1 year (range 1-39 weeks). There was no difference in relapse after 1 year in the nicotine group between those who used the spray for 1 year and those who stopped earlier (difference 5%, 95% confidence interval −33% to 43%).
Comment
Our results show that the spray is an effective aid to long term smoking cessation and that those who used the spray for 1 year had a similar relapse profile to those who stopped using it earlier. They also indicate substantial relapse after the time that most studies have completed their final follow up to assess treatment efficacy. Although the success ratio of active to placebo treatment (about 2.5) was unchanged by relapse, the absolute difference was reduced considerably, and hence the estimated number needed to treat to achieve each success was increased (from 6.3 to 10.8). Our relapse rate is similar to that in a trial of nicotine patches (37% between years 1 and 3) 3 and in a study using supportive counselling and nicotine gum for 5 years (40% between years 1 and 5). 4 High relapse rates after 1 year are also common in those not attending for treatment. A large general population survey estimated a relapse rate of 35% from non-validated self reports of the duration of abstinence.
5
Success rates after 1 year or less of follow up substantially overestimate lifelong cessation after a single treatment episode.
Contributors: MAHR, GS, and JAS designed the original study, which GS conducted. JAS and GS designed the long term follow up phase, which GS conducted. JAS analysed the data and wrote the text of the paper. JAS and GS will act as guarantors for the paper. 2 Good services to manage deliberate self poisoning in general hospitals might therefore help to achieve the targets set out by the Health of the Nation strategy to reduce suicide rates. Existing services have not been planned coherently; the care provided by hospitals varying greatly, even in the same region. 3 We assessed the management of self poisoning in four teaching hospitals in England by using standardised methods of notification.
Subjects, methods, and results
We prospectively identified all patients over 16 years of age who attended four teaching hospitals in Leeds, Leicester, Manchester, and Nottingham for deliberate self poisoning during 4 weeks (November to December 1996). We obtained data by examining computerised databases on wards and in the accident and emergency department, referral ledgers, accident and emergency notes, and copies of specialist assessments of deliberate self poisoning. We checked all inpatient data retrospectively against information on admission and discharge for deliberate self poisoning that we obtained from the patient administration system in each hospital. We collected demographic details of patients, along with details of substance dependence, previous overdoses, and contact with psychiatric services. We also recorded information on the management of the current episode of self poisoning.
During the study period 458 patients accounted for 477 hospital attendances for deliberate self poisoning; 223 (49%) of these were women. The mean age of the patients was 30.9 years (SD 11.8 years); 65 (14%) were dependent on alcohol or drugs, 177 (39%) had taken a previous overdose, and 119 (26%) were in contact with psychiatric services. These percentages and the substances ingested were similar across study centres. By contrast, there were striking variations in the management of episodes between study centres, with a fourfold difference in discharge rates from accident and emergency departments, and almost a twofold difference in the proportion of subjects receiving a specialist psychosocial assessment (table). In 220 out of 477 hospital attendances (46%) the patient had no psychosocial assessment at any time during their hospital contact.
